as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹291.15
Change
-1.6 (-0.55%)
Open
₹292.75
Prev. Close
₹292.75
Day High
₹297.0
Day Low
₹290.0
Volume Analysis
Traded
185,804
Delivered
113,336
Delivery %
61.0%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (30.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (16.8%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹302.44 | ₹299.72 | ₹295.44 | ₹292.72 | ₹288.44 | ₹285.72 | ₹281.44 |
| Fibonacci | ₹299.72 | ₹297.05 | ₹295.39 | ₹292.72 | ₹290.05 | ₹288.39 | ₹285.72 |
| Camarilla | ₹293.08 | ₹292.43 | ₹291.79 | ₹292.72 | ₹290.51 | ₹289.87 | ₹289.23 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-4.24%
1 Week
-0.99%
1 Month
-2.89%
3 Months
-5.32%
6 Months
+9.29%
1 Year
-9.02%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹222.5
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.53%
Net margin 22.93% × asset turnover 0.41x × equity multiplier 1.12x
Company Overview
Sector
Healthcare
Market Cap
₹3,278 Cr
P/E (TTM)
20.8
ROE
10.2%
Book Value
₹146.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Advanced Enzyme Tech Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Momentum (24/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (30.0%); promoter holding is falling. Strong 3-year EPS growth (16.8%).
TopFund Score — Fundamentals Quality
65/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 40.9%
- −The company has delivered a poor sales growth of 8.24% over past five years.
- −Company has a low return on equity of 10.3% over last 3 years.
- −Promoter holding has decreased over last 3 years: -3.27%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
September 24, 2026 buyback report: 64,668 shares bought at ₹298.03; cumulative buyback 15,88,324 shares.
Advanced Enzyme bought 1,136 shares on Sept 22, 2026; cumulative buyback reached 14,60,040 shares.
Advanced Enzyme bought back 50,000 shares on September 21, 2026; cumulative buyback reached 14,58,904 shares.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 147 | 158 | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 |
| Expenses + | 103 | 107 | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 |
| Operating Profit | 44 | 51 | 54 | 55 | 51 | 42 | 55 | 46 | 56 | 60 | 49 | 63 | 51 |
| OPM % | 30.0% | 32.0% | 33.0% | 35.0% | 33.0% | 29.0% | 33.0% | 27.0% | 30.0% | 33.0% | 29.0% | 31.0% | 27.0% |
| Other Income + | 7 | 6 | 14 | -6 | 7 | 10 | 8 | 9 | 9 | 10 | 20 | 7 | 13 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 |
| Profit before tax | 41 | 48 | 59 | 40 | 49 | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 |
| Tax % | 29.0% | 27.0% | 28.0% | 25.0% | 28.0% | 21.0% | 27.0% | 38.0% | 26.0% | 25.0% | 26.0% | 24.0% | 28.0% |
| Net Profit + | 29 | 35 | 42 | 30 | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 |
| EPS in Rs | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 2 | 4 | 4 | 4 | 4 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 746 | 750 |
| Expenses + | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 382 | 418 | 441 | 515 | 526 |
| Operating Profit | 91 | 138 | 152 | 165 | 184 | 203 | 232 | 203 | 158 | 206 | 196 | 230 | 224 |
| OPM % | 41.0% | 47.0% | 46.0% | 42.0% | 44.0% | 46.0% | 46.0% | 38.0% | 29.0% | 33.0% | 31.0% | 31.0% | 30.0% |
| Other Income + | 1 | -3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | 21 | 33 | 46 | 50 |
| Interest | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 5 | 4 | 2 |
| Depreciation | 9 | 9 | 13 | 18 | 21 | 26 | 28 | 35 | 35 | 35 | 37 | 40 | 40 |
| Profit before tax | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 233 | 231 |
| Tax % | 31.0% | 35.0% | 32.0% | 33.0% | 28.0% | 26.0% | 28.0% | 28.0% | 26.0% | 27.0% | 28.0% | 25.0% | — |
| Net Profit + | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 174 | 172 |
| EPS in Rs | 5 | 7 | 8 | 8 | 10 | 12 | 13 | 11 | 9 | 12 | 12 | 15 | 15 |
| Dividend Payout % | 4.0% | 3.0% | 5.0% | 6.0% | 6.0% | 5.0% | 7.0% | 9.0% | 11.0% | 43.0% | 44.0% | 36.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 188 | 256 | 442 | 537 | 657 | 817 | 948 | 1,066 | 1,213 | 1,302 | 1,398 | 1,610 |
| Borrowings + | 115 | 101 | 54 | 67 | 35 | 28 | 23 | 35 | 34 | 47 | 39 | 32 |
| Other Liabilities + | 92 | 71 | 65 | 102 | 91 | 104 | 153 | 137 | 142 | 150 | 151 | 170 |
| Total Liabilities | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 |
| Fixed Assets + | 287 | 285 | 421 | 491 | 495 | 563 | 601 | 619 | 649 | 650 | 679 | 692 |
| CWIP | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 22 | 51 |
| Investments | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 480 | 584 |
| Other Assets + | 125 | 158 | 153 | 226 | 188 | 275 | 413 | 524 | 380 | 427 | 430 | 507 |
| Total Assets | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 |
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 54 | 93 | 107 | 116 | 129 | 141 | 163 | 122 | 140 | 141 | 142 | 157 |
| Cash from Investing Activity + | -15 | -10 | -60 | -60 | -124 | -43 | -27 | 2 | -286 | -65 | -89 | -72 |
| Cash from Financing Activity + | -36 | -63 | -65 | -2 | -43 | -39 | -26 | -48 | -26 | -59 | -73 | -70 |
| Net Cash Flow | 2 | 21 | -18 | 54 | -38 | 60 | 109 | 75 | -171 | 17 | -20 | 15 |
| CFO/OP | 88 | 88 | 105 | 97 | 70 | 94 | 94 | 87 | 112 | 93 | 103 | 96 |
| Free Cash Flow | 42 | 88 | 97 | 105 | 116 | 90 | 143 | 95 | 102 | 94 | 108 | 105 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 25.34% | 26.88% | 25.95% | 36.87% | 36.4% | 36.31% | 36.82% | 25.0% | 25.09% | 25.62% | 25.85% | 25.28% |
| Promoters | 45.92% | 43.62% | 43.5% | 43.02% | 42.95% | 42.92% | 43.08% | 43.08% | 43.08% | 43.04% | 43.26% | 43.25% |
| FII | 22.27% | 22.54% | 23.01% | 12.03% | 12.63% | 12.57% | 11.9% | 23.45% | 25.41% | 25.85% | 25.5% | 26.7% |
| DII | 6.49% | 6.98% | 7.56% | 8.08% | 8.02% | 8.17% | 8.19% | 8.45% | 6.41% | 5.51% | 5.41% | 4.77% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Advanced Enzyme Tech Ltd (this stock) | 3,278 | 20.8 | 2.01 | 10.2% |
| Ind Swift Laboratories Lt | 3,489 | 53.6 | 2.52 | 3.87% |
| Solara Active Pha Sci Ltd | 3,587 | 840.0 | 2.14 | -0.13% |
| Kwality Pharmaceuticals L | 3,824 | 46.8 | 11.48 | 22.6% |
| Hikal Limited | 2,731 | 64.4 | 2.28 | 2.21% |
| Dishman Carbo Amcis Ltd | 2,718 | 150.0 | 0.41 | 1.58% |
| Unichem Laboratories Ltd | 3,870 | 31.7 | 1.42 | 3.17% |
Which Mutual Funds Hold Advanced Enzyme Tech Ltd?
Frequently Asked Questions about Advanced Enzyme Tech Ltd
Advanced Enzyme Tech Ltd (ADVENZYMES) closed at ₹291.15 on NSE on 25 September 2026, down 1.6 (0.55%) from the previous close.
Advanced Enzyme Tech Ltd trades on the NSE (National Stock Exchange of India) under the symbol ADVENZYMES.
Advanced Enzyme Tech Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 20.8.
Advanced Enzyme Tech Ltd has a dividend yield of 1.83%.
Advanced Enzyme Tech Ltd's 52-week high is ₹420.0 and its 52-week low is ₹252.0.
Advanced Enzyme Tech Ltd has a market capitalisation of ₹3,278 crore.
Advanced Enzyme Tech Ltd has a TopFund Quality Score of 65/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Advanced Enzyme Tech Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.